A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Taiwan shuttlers dominate mixed doubles at World University Games
07/26/2025 10:23 PM - Politics
Recall failure a victory for Taiwan's people: KMT chairman
07/26/2025 09:45 PM - Politics
All 24 KMT lawmakers, Hsinchu mayor survive recall votes (update)
07/26/2025 09:12 PM - Politics
DPP acknowledges failure of mass recall campaign
07/26/2025 08:10 PM - Politics
Suspended Hsinchu Mayor Kao Hung-an survives recall vote
07/26/2025 07:35 PM